Clinical take In adults with T2D + established ASCVD, tirzepatide demonstrated CV safety comparable to dulaglutide on MACE-3 a meaningful benchmark for decision-making in real practice
Some patients experience more intensity at the 2.4 mg Wegovy dose, but many tolerate it just as well as lower doses because the body has fully adapted by that point
Retrieved from Patel, P., Nessel, T
Tirzepatide is a first-in-class dual incretin receptor agonist a single molecule that activates both the GIP (glucose-dependent insulinotropic polypeptide) and the GLP-1 (glucagon-like peptide-1) receptors, which is why it is often nicknamed a twincretin. [7] By engaging two incretin pathways it enhances glucose-dependent insulin secretion, promotes satiety, and delays gastric emptying, producing large effects on both glycemic control and bodyweight
Phoenix Pharmaceuticals, also known as Phoenix Peptide, is one of the most historically significant peptide suppliers in North America, founded in 1969 by the scientist who synthesized thyrotropin-releasing hormone (TRH), foundational work that contributed to the discovery of the first neuropeptides